Table 3.
Overview: acute, subacute and late side effects with grading
| Acute |
Subacute (<6 months) |
Chronic (>6 months) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grading | G1 | G2 | G3 | G4 | G1 | G2 | G3 | G4 | G1 | G2 | G3 | G4 |
| Radiotherapy | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) |
| Mucositis | 8 (3.4) | 12 (5.0) | 5 (2.1) | / | 1 (0.4) | 4 (1.7) | / | / | / | / | / | / |
| Bleeding | 1 (0.4) | / | / | / | 1 (0.4) | / | / | / | / | / | 1 (0.4) | / |
| Stricture | / | / | 1 (0.4) | / | / | / | 10 (4.2) | / | / | / | 10 (4.2) | / |
| Fistula | 1 (0.4) | / | / | / | / | 2 (0.8) | / | / | / | / | 1 (0.4) | / |
| Xerostomia | 4 (1.7) | / | / | / | 2 (0.8) | 1 (0.4) | / | / | 4 (1.7) | 1 (0.4) | / | / |
| Nausea | 21 (8.8) | 17 (7.1) | 7 (2.9) | / | / | / | / | / | / | / | / | / |
| Dysphagia | 34 (14.3) | 67 (28.2) | 29 (12.2) | 1 (0.4) | 17 (7.1) | 15 (6.3) | 5 (2.1) | 3 (1.3) | 26 (10.9) | 23 (9.7) | 10 (4.2) | 1 (0.4) |
| Dermatitis | 43 (18.1) | 17 (7.1) | 9 (3.8) | / | 6 (2.5) | 2 (0.8) | / | / | 4 (1.7) | 4 (1.7) | / | / |
| Cardiac toxicity | / | 1 (0.4) | / | / | / | / | / | / | / | / | / | / |
| Pulmonary toxicity | 3 (1.3) | / | / | / | 1 (0.4) | 4 (1.7) | / | / | 2 (0.8) | 4 (1.7) | 1 (0.4) | / |
| Chemotherapy | No. (%) | No. (%) | No. (%) | No. (%) | ||||||||
| Leucopenia | 4 (2.6) | 15 (9.9) | 12 (7.9) | / | ||||||||
| Pancytopenia | 1 (0.7) | 11 (7.2) | 6 (3.9) | / | ||||||||
| Nausea | 18 (11.8) | 58 (38.2) | 23 (15.1) | 2 (1.3) | ||||||||
| Emesis | 29 (19.1) | 31 (20.4) | 19 (12.5) | / | ||||||||
| Diarrhea | 4 (2.6) | 1 (0.7) | 2 (1.3) | / | ||||||||
| Edema | 2 (1.3) | 6 (3.9) | 1 (0.7) | / | ||||||||
| Hearing loss | 1 (0.7) | 2 (1.3) | 2 (1.3) | / | ||||||||